ClinicalTrials.govpublic full text
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
colorectal neuroendocrine tumor g1, gastric neuroendocrine tumor g1, neuroendocrine neoplasm, neuroendocrine tumor, neuroendocrine tumor g2, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 874999
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.